Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy

被引：47

作者：

Durrant, L. G. ^{[1
]}

Noble, P. ^{[1
]}

Spendlove, I. ^{[1
]}

机构：

[1] Univ Nottingham, City Hosp, Acad Dept Clin Oncol, Nottingham NG5 1PB, England

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2012年 / 167卷 / 02期

关键词：

cancer vaccine; glycolipid; glycosylation; immunotherapy; monoclonal antibody; CELL-LUNG-CANCER; ALPHA-5-BETA-1 INTEGRIN RECEPTOR; MOUSE MONOCLONAL-ANTIBODIES; N-GLYCOLYLNEURAMINIC ACID; HUMAN BREAST-CANCER; SIALYL-LEWIS-X; GM3; GANGLIOSIDE; MELANOMA PATIENTS; CONJUGATE VACCINE; ADJUVANT VACCINATION;

D O I：

10.1111/j.1365-2249.2011.04516.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. This has resulted in the development of a number of vaccines and monoclonal antibodies that are showing promising results in recent clinical trials.

引用

页码：206 / 215

页数：10

共 50 条

[31] Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy
Walter Bodmer
British Journal of Cancer, 2023, 128 : 419 - 420
[32] Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes
Lind, K.
Huehn, M. H.
Flodstrom-Tullberg, M.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 168 (01): : 30 - 38
[33] Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes
Hober, D.
Sane, F.
Jaidane, H.
Riedweg, K.
Goffard, A.
Desailloud, R.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2012, 168 (01): : 47 - 51
[34] Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy COMMENT
Bodmer, Walter
BRITISH JOURNAL OF CANCER, 2023, 128 (03) : 419 - 420
[35] A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Khadela, Avinash
Postwala, Humzah
Rana, Deval
Dave, Hetvi
Ranch, Ketan
Boddu, Sai H. S.
MEDICAL ONCOLOGY, 2023, 40 (05)
[36] A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Avinash Khadela
Humzah Postwala
Deval Rana
Hetvi Dave
Ketan Ranch
Sai H. S. Boddu
Medical Oncology, 40
[37] Perspectives on COVID-19 and cancer immunotherapy: a review series
Goldman, Jason D.
Ascierto, Paolo Antonio
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (03)
[38] Nucleolin-based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)
Thongchot, Suyanee
Aksonnam, Krittaya
Thuwajit, Peti
Yenchitsomanus, Pa-Thai
Thuwajit, Chanitra
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2023, 52 (03)
[39] Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II
Xu, Caili
Ju, Dianwen
Zhang, Xuyao
FRONTIERS IN IMMUNOLOGY, 2023, 14
[40] Cancer immunotherapy with soluble T cell receptors; Intracellular tumour proteins become valid targets for treatment
Brewer, JE
Sutton, DH
Purbhoo, MA
Lissin, N
Johnson, A
Molloy, P
Dunn, SM
Moysey, R
Depta, J
Mullings, RE
Pumphrey, N
Li, Y
Jakobsen, BK
ANNALS OF ONCOLOGY, 2006, 17 : 48 - 48

← 1 2 3 4 5 →